ARCHIVES

FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225.

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

ODAC Clarifies Standards for Maintenance In Ovarian Cancer; Nixes Olaparib in 11-2 Vote

June 27, 2014

Thompson Tours Brown’s Brain Science Center.

March 16, 2001

Plaza Dedicated At NIH In Honor Of Paul Rogers.

June 15, 2001

In Brief: Paul Van Nevel, Director Of NCI Communications, To Retire At Year’s End

November 26, 1999

In Brief: Selection Of NCI Director Extended By Month; Fisher Named NSABP Scientific Director

March 17, 1995